Antioxidant exposure; formulation-specific skin
Study
Scope of investigation or explicitly identified community interest; not an established indication.1
Longevity
Glutathione
An antioxidant with formulation-specific evidence
Investigational; this profile does not establish an approved use.
What does it do?
Molecular information
1Amino-acid sequence
- γ-Glu
- Cys
- Gly
3 residues · N → C1
Length3 amino acids
Molecular weight · DaNot independently verified
Molecular formulaNot independently verified1
γE–C–GγE = gamma-glutamyl linkage, distinct from an ordinary alpha-peptide bond.
Sequence and formulation must be confirmed for the exact material; similarly named products are not necessarily interchangeable.
Pharmacokinetics
Reported half-lifeHuman kinetics not established1
No numerical human elimination estimate is assigned from animal experiments, related molecules, or an unsupported website estimate.
No numerical estimate was found in the checked data or Pep-Pedia profile. A curve would require an unsupported assumption.
What to expect
Study outcomes
Scope of evidence
Oral findings do not establish injectable safety or an anti-aging effect.1
Doses & schedules
Route
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| Oral | 300 mg — micellar formulation | Single administrations in a crossover design | Oral exposure comparison14 healthy adultsHuman study | Acute crossover | 1 |
Population 14 healthy adults Context Product-specific pharmacology, not an injection protocol. Source dose wording Micellar 300 mg; standard comparator 500 mg | |||||
| Oral | 500 mg — standard comparator | Single administrations in a crossover design | Oral exposure comparison14 healthy adultsHuman study | Acute crossover | 1 |
Population 14 healthy adults Context Product-specific pharmacology, not an injection protocol. Source dose wording Micellar 300 mg; standard comparator 500 mg | |||||
| IMIntramuscular | 200-400 mg | 1-2x weekly | General antioxidant supportReference report | 4-8 weeks typical | 15 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. NAC supports glutathione synthesis; glutathione itself is not a substitute for established acetaminophen-overdose treatment. Source route wording IM or IV push Source tabs Injectable | |||||
| IVIntravenous | 200-400 mg | 1-2x weekly | General antioxidant supportReference report | 4-8 weeks typical | 15 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. NAC supports glutathione synthesis; glutathione itself is not a substitute for established acetaminophen-overdose treatment. Source route wording IM or IV push Source tabs Injectable | |||||
| IVIV push or slow infusion | 400-600 mg | 2-3x weekly | Detoxification supportReference report | 4-8 weeks typical | 15 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. NAC supports glutathione synthesis; glutathione itself is not a substitute for established acetaminophen-overdose treatment. Source tabs Injectable | |||||
| IMIntramuscular | 400-600 mg | 1-2x weekly | Immune supportReference report | 4-8 weeks typical | 15 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. NAC supports glutathione synthesis; glutathione itself is not a substitute for established acetaminophen-overdose treatment. Source route wording IV or IM Source tabs Injectable | |||||
| IVIntravenous | 400-600 mg | 1-2x weekly | Immune supportReference report | 4-8 weeks typical | 15 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. NAC supports glutathione synthesis; glutathione itself is not a substitute for established acetaminophen-overdose treatment. Source route wording IV or IM Source tabs Injectable | |||||
| IVIV infusion (clinical protocol) | 1400 mg | 3x weekly | Neurological support (Parkinson's research)Reference report | 4-8 weeks typical | 15 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. NAC supports glutathione synthesis; glutathione itself is not a substitute for established acetaminophen-overdose treatment. Source tabs Injectable | |||||
| SubQSubcutaneous | 200 mg | 1x weekly | MaintenanceReference report | 4-8 weeks typical | 15 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. NAC supports glutathione synthesis; glutathione itself is not a substitute for established acetaminophen-overdose treatment. Source route wording IM or SubQ Source tabs Injectable | |||||
| IMIntramuscular | 200 mg | 1x weekly | MaintenanceReference report | 4-8 weeks typical | 15 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. NAC supports glutathione synthesis; glutathione itself is not a substitute for established acetaminophen-overdose treatment. Source route wording IM or SubQ Source tabs Injectable | |||||
| OralOral (liposomal preferred) | 250-500 mg | Daily | General antioxidant supportReference report | Can be used ongoing | 15 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. NAC supports glutathione synthesis; glutathione itself is not a substitute for established acetaminophen-overdose treatment. Source tabs Oral | |||||
| OralOral liposomal or Sublingual | 500-1000 mg | Daily, divided doses | Enhanced supportReference report | Can be used ongoing | 15 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. NAC supports glutathione synthesis; glutathione itself is not a substitute for established acetaminophen-overdose treatment. Source tabs Oral | |||||
| IntranasalNasal spray | 100-200 mg per nostril | 3x daily | Neurological support (PD research protocol)Reference report | 3+ months for neurological applications | 15 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. NAC supports glutathione synthesis; glutathione itself is not a substitute for established acetaminophen-overdose treatment. Source tabs Nasal | |||||
| IntranasalNasal spray | 100 mg per nostril | 1-2x daily | General brain health supportReference report | 3+ months for neurological applications | 15 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. NAC supports glutathione synthesis; glutathione itself is not a substitute for established acetaminophen-overdose treatment. Source tabs Nasal | |||||
| OtherApply to face/target areas | 2-5% cream or serum | 1-2x daily | Skin brighteningReference report | Ongoing use required to maintain any effects | 15 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. NAC supports glutathione synthesis; glutathione itself is not a substitute for established acetaminophen-overdose treatment. Source tabs Topical | |||||
| OtherApply after cleansing | 2% cream | Daily | Antioxidant skin supportReference report | Ongoing use required to maintain any effects | 15 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. NAC supports glutathione synthesis; glutathione itself is not a substitute for established acetaminophen-overdose treatment. Source tabs Topical | |||||
No protocols match these filters.
Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.
Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.
Injectable
- Use period
- 4-8 weeks typical
- Break
- 4 weeks off after 4-8 weeks on is commonly recommended, though some protocols allow ongoing use
Reported timing
No specific timing required. Some prefer morning administration. IV often given in clinical settings.
Oral
- Use period
- Can be used ongoing
- Break
- Not typically required for oral supplementation
Reported timing
Morning preferred. Can split into morning and evening doses.
Nasal
- Use period
- 3+ months for neurological applications
- Break
- Not established - ongoing use studied
Reported timing
Can be used any time of day. Space doses evenly throughout the day for multiple daily doses.
Topical
- Use period
- Ongoing use required to maintain any effects
- Break
- Not required
Reported timing
Evening application common. Use sunscreen during day if using for skin lightening.
Side effects & safety
Route boundary
Oral pharmacology cannot establish the safety of IV, IM or nebulized glutathione.
1Small short-term study
A 14-person exposure study cannot rule out uncommon or long-term adverse effects.
1Serious reactions
Anaphylaxis, liver injury and injection infection possible; jaundice, dark urine, breathing difficulty or unusual bruising need assessment.
Route-related effects
GI upset, nasal/skin irritation; inhaled forms may worsen asthma.
Uncertain high-dose safety
Source flags G6PD hemolysis and zinc depletion; pregnancy/lactation safety unestablished.
Not a complete safety screen. Discuss health decisions with a qualified clinician.
Combinations & interactions
3 entriesCheck cautions and reported pairings. A compatibility claim does not establish that a combination is safe.
Chemotherapy
Caution reportedOncology review; possible treatment interference.15
Reference report · Evidence context: Use cautionVitamin C / niacinamide
Unverified pairingProposed antioxidant/topical complement; no general safety conclusion.15
Reference report · Evidence context: Reference pairingOther peptides and medicines
Not establishedA controlled interaction assessment for this exact compound and formulation was not identified in the sources checked. Absence of interaction data is not evidence of compatibility.2
Research contextNo matching interactions. Try another name or filter.
Reconstitution
A product-specific preparation or sterility protocol has not been verified.2
Dilution
A concentration calculation cannot establish a suitable diluent, compatibility, storage interval, or sterility. No universal bacteriostatic-water volume is assigned.2
Reference preparation details
Reported handling information, not a validated formulation or instruction to prepare an injectable product.
Injectable
The source describes mostly premixed injections and product-specific handling of dry material.
- Form
- Source describes a prepared product
- Reported parameters
- It distinguishes IM/subcutaneous presentation from clinician-administered IV dilution.
Oral
Pep-Pedia repeats injection preparation text in this route view.
That repeated text does not establish an oral, nasal or topical formulation; use route-specific product instructions.
Nasal
Pep-Pedia repeats injection preparation text in this route view.
That repeated text does not establish an oral, nasal or topical formulation; use route-specific product instructions.
Topical
Pep-Pedia repeats injection preparation text in this route view.
That repeated text does not establish an oral, nasal or topical formulation; use route-specific product instructions.
Appearance & documentation
Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.
Reported appearanceLicensed Compounding PharmacyReported appearanceProper Form (Reduced GSH)Reported appearanceClear LabelingReported appearanceHealthcare Provider SupervisionReported variationpH Affects ComfortReported variationShort Half-LifeReported variationVariable BioavailabilityReported concernUnregulated Sources
15Available forms
No verified packaging examples included.
Packaging examples, not a market survey. Approved and research products are not interchangeable.
Storage after mixing
Reconstituted research vials
Refrigerated lifetime not established
The checked sources do not establish how long this research preparation remains stable and sterile after mixing.15
Storage notes
15Refrigerate at 2-8°C (36-46°F). Protect from light. Do not freeze. Use within manufacturer's expiration date.
Room temperature, away from heat and moisture. Refrigerate liposomal products after opening if directed.
Refrigerate. Protect from light.
Per product instructions - typically room temperature away from light
Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.
Evidence limits
View findings →Oral findings do not establish injectable safety or an anti-aging effect.1
2 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.
Evidence definitions →Research findings
Human trialsSource context
NAC supports glutathione synthesis; glutathione itself is not a substitute for established acetaminophen-overdose treatment.
Compound identity & other names
Glutathione is an endogenous tripeptide involved in redox chemistry. Oral, topical, inhaled and injectable formulations are different interventions; increasing a blood biomarker does not itself demonstrate better health.
Other names: GSH · Reduced glutathione
Investigational; this profile does not establish an approved use.
Reduced glutathione; γ-glutamyl-cysteinyl-glycine1
How it may work
Redox regulation, antioxidant recycling and conjugation; oral, liposomal, nasal and topical delivery have different evidence.15
Oral formulation bioavailability
A micellar product produced greater exposure than comparison products. Doses and formulations differed; short biomarker follow-up cannot establish long-term health benefit.
1Source checks & newer research
Phase IIb Study of Intranasal Glutathione in Parkinson's Disease
In 45 participants over 3 months, neither glutathione arm improved symptoms more than placebo. Improvement from baseline alone did not establish efficacy.
Human randomized placebo-controlled trial16Research areas and evidence gaps
Antioxidant exposure; formulation-specific skin research. Scope of investigation or explicitly identified community interest; not an established indication.1
- Oral findings do not establish injectable safety or an anti-aging effect.
- The evidence does not validate the identity, purity or handling of a separately sourced research product.
Additional uses listed by Pep-Pedia
Antioxidant and liver biology. Redox and detoxification pathways; not a proven general detox treatment.15
Immune function. T-cell, NK-cell and macrophage research.15
Neurological disease. Preliminary Parkinson research; efficacy over placebo not demonstrated.15
Skin appearance. Modest/temporary lightening claims; IV cosmetic use carries serious concerns.15
Community reports Unvalidated
Pep-Pedia reports use in the research-peptide community. These reports are not clinical evidence.2
Community protocol tables are unvalidated descriptions, not treatment instructions.
Search coverage and review status
Additional recent evidence was checked, including A Targeted Metabolomic Assessment of Oral Glutathione Bioavailability and Safety in Humans: A Randomized Crossover Clinical Trial. See individual source summaries for findings and limitations.
- Checked
- 2026-10-12
- Search
- glutathione randomized trial 2025 2026 oral skin
- Catalog
- Pep-Pedia ↗ · 12 listed references retained
- Targeted search, not a systematic or exhaustive review.
- Retained bibliography entries marked Bibliography only have not been independently verified.
- Distinct URLs may refer to the same publication; component and formulation boundaries remain important.
AI-prepared summaries. Independent medical editorial review is pending.
Community poll 10 topics · Pep-Pedia snapshot
Voluntary, unverified reports. These percentages do not measure effectiveness or safety.
Experience
Number of responses to this question: not disclosed.
Duration of use
The source hides 4 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Age range
The source hides 2 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Gender
Number of responses to this question: not disclosed.
Primary goal
The source hides 12 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Effectiveness
The source hides 16 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Side effects
The source hides 15 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Dosage frequency
The source hides 5 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Would recommend
The source hides 4 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
How discovered
The source hides 3 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Source & limitations
The source displays “1730 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.
- Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
- The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
- Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
- Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
- This is a dated snapshot, not a live survey or current recommendation.
References
Original sources and review status. Open a reference to read its summary.
1A Targeted Metabolomic Assessment of Oral Glutathione Bioavailability and Safety in Humans: A Randomized Crossover Clinical TrialAbstract checked
AI-PREPARED SUMMARY
A 14-person oral crossover trial compared bioavailability of different glutathione formulations.
Oral formulation bioavailability
A micellar product produced greater exposure than comparison products. Doses and formulations differed; short biomarker follow-up cannot establish long-term health benefit.
Additional research · Checked 2026-10-12
2Pep-Pedia: GlutathioneCommunity source checked
AI-PREPARED SUMMARY
Secondary community overview checked on 12 October 2026. Its practice tables and efficacy claims are not independently validated clinical guidance.
3Aebi, S., Assereto, R., Lauterburg, B.H. (1991). High-dose intravenous glutathione in man: Pharmacokinetics and effects on cyst(e)ine in plasma and urine. European Journal of Clinical Investigation, 21(1), 103-110.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Plasma glutathione rose rapidly after IV exposure and then declined with a reported half-life near 14 minutes.
Reported population / model
Human
Reported study details
2g/m² IV infusion · Rapid clearance · t½ ~14 minutes
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
4Sian, J., Dexter, D.T., Lees, A.J., et al. (1994). Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Annals of Neurology, 36(3), 348-355.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Postmortem Parkinson's brain samples reportedly had about 40% lower substantia-nigra glutathione; this does not establish benefit from supplementation.
Reported population / model
Human
Reported study details
Post-mortem · 40% reduction in substantia nigra
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
5Phase IIb Study of Intranasal Glutathione in Parkinson's DiseasePrimary source checked
AI-PREPARED SUMMARY
In 45 participants over 3 months, neither glutathione arm improved symptoms more than placebo. Improvement from baseline alone did not establish efficacy.
Pep-Pedia bibliography; reconciled with an existing checked primary-source record · Checked 2026-10-12
6Glutathione for Skin Lightening - Systematic Review (2025)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The review describes limited skin-lightening evidence, modest oral/topical signals and greater safety concerns for IV use.
Reported population / model
Review
Reported study details
Multiple RCTs · Oral, IV, topical forms
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
7Droge, W., & Breitkreutz, R. (2000). Glutathione and immune function. Proceedings of the Nutrition Society, 59(4), 595-600.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The review links intracellular glutathione availability with T-cell proliferation and natural-killer activity; supplementation outcomes are a separate question.
Reported population / model
Review
Reported study details
Lymphocyte function · GSH depletion effects
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
8GSH in Liver Detoxification - Phase II ConjugationPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Glutathione participates in conjugation and removal of xenobiotics; its physiological role alone does not prove a benefit from extra dosing.
Reported population / model
Review
Reported study details
Hepatic metabolism · Xenobiotic detoxification
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
9Lu, S.C. (2013). Glutathione synthesis. Biochimica et Biophysica Acta, 1830(5), 3143-3153.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
10Aebi, S., Assereto, R., Lauterburg, B.H. (1991). High-dose intravenous glutathione in man: Pharmacokinetics and effects on cyst(e)ine in plasma and urine. European Journal of Clinical Investigation, 21(1), 103-110.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
11Sian, J., Dexter, D.T., Lees, A.J., et al. (1994). Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Annals of Neurology, 36(3), 348-355.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
12Mischley, L.K., Lau, R.C., Shankland, E.G., Wilbur, T.K., Padowski, J.M. (2017). Phase IIb Study of Intranasal Glutathione in Parkinson's Disease. Journal of Parkinson's Disease, 7(2), 289-299.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
13Droge, W., & Breitkreutz, R. (2000). Glutathione and immune function. Proceedings of the Nutrition Society, 59(4), 595-600.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
14Lu, S.C. (2013). Glutathione synthesis. Biochimica et Biophysica Acta, 1830(5), 3143-3153.Linked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography. The original source and the website’s description have not been independently verified; the listed title may not match the linked record.
Pep-Pedia bibliography · Checked 2026-10-12
15Pep-Pedia: Glutathione — route-specific referenceReference page checked; underlying claims require separate verification.Community source checked
AI-PREPARED SUMMARY
Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.
Content coverage audit · Checked 2026-10-12
16Phase IIb Study of Intranasal Glutathione in Parkinson's DiseasePrimary source checked
AI-PREPARED SUMMARY
In 45 participants over 3 months, neither glutathione arm improved symptoms more than placebo. Improvement from baseline alone did not establish efficacy.
Phase IIb Study of Intranasal Glutathione in Parkinson's Disease
In 45 participants over 3 months, neither glutathione arm improved symptoms more than placebo. Improvement from baseline alone did not establish efficacy.
Additional primary-source check · Checked 2026-10-12